Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ian Schofield

Edinburgh, U.K
Ian Schofield has been writing on issues affecting the pharmaceutical and biotech industry since the mid-1980s, specialising in EU and global policy and regulatory affairs.  As well as writing, editing and commissioning articles for Pharma Intelligence, Ian works for the Ask the Analyst service, providing tailor-made answers to questions posed directly by clients. He has a degree in modern languages from the University of Bath. Outside the realm of work, Ian plays guitar in a traditional music group and also enjoys a touch of cycling and gardening. He lives by the seaside about three miles from the centre of Edinburgh.
Advertisement
Set Alert for Articles By Ian Schofield

Latest From Ian Schofield

French To Press On With Rapid Trial Approval System

A French pilot intended to speed up the authorization of clinical trials is to be continued after a pilot phase showed it was working well.

France Clinical Trials

Scotland Explains How To Tackle No-Deal Drug Shortages

Scotland’s government has consistently opposed the UK’s departure from the EU, and has been putting its own measures in place to deal with any medicines shortages that might arise in the event of a no-deal Brexit.

United Kingdom Brexit

UK Signs Three More No-Deal Brexit Drug Transport Contracts

Efforts to ensure that supplies of medicines continue to flow if the UK leaves the EU without a deal have been stepped up with the announcement of three contracts to provide an express delivery service for urgently needed products.

United Kingdom Brexit

Reprieve For Life Sciences As Brexit Deal Approved

The Brexit withdrawal deal agreed by the UK and the EU on 17 October would see the UK leave the EU at the end of the month, but would allow time to negotiate the future trading and regulatory relationship between the two parties. However, the deal still faces a rough passage in the UK parliament.

United Kingdom Brexit

Reprieve For Life Sciences As Brexit Deal Approved

The Brexit withdrawal deal agreed by the UK and the EU on 17 October would see the UK leave the EU at the end of the month but would allow time to negotiate the future trading and regulatory relationship between the two parties. However, the deal still faces a rough passage in the UK parliament.

United Kingdom Brexit

UK Bill To Speed Up Post-Brexit Access To Innovative Drugs

A new bill giving the UK regulator more powers after Brexit has been welcomed by the life sciences industry. However, observers have warned that it needs fleshing out with detail, and that the government would be wise to proceed carefully if it considers relaxing clinical trial regulations.

United Kingdom Brexit
See All
Advertisement
UsernamePublicRestriction

Register